Prediction of potential toxicities is a vital step during the early stage of drug discovery. The leading reasons for drug attrition and drug withdrawal are hepatotoxicity, cardiotoxicity, nephrotoxicity and neurotoxicity, which account for more than 70%. Drug toxicity testing can save both costs and time by reducing the chance of failure in clinic assays.
Creative Bioarray is an ideal partner to test the potential toxicities of candidate drug compounds using a panel of cell-based assays. Creative Bioarray has developed highly predictive cellular models from a wide range of sources and is equipped with the most advanced high content analysis (HCA) platforms, which use automated fluorescence imaging in a high-throughput way. The state-of-the-art technologies allow us to rapidly and automatically provide high-quality data for safety profiling and dissecting signaling pathways involved in the drug toxicity.
As the primary organ involved in detoxification, drug-induced liver toxicity (DILI) is the leading cause of drug failures. Creative Bioarray has developed a series of assays using primary hepatocytes, HepG2 cell lines and 3D hepatic models to predict DILI.
Cardiotoxicity is another significant issue during drug development. Based on the iPS/ES cell-derived cardiomyocytes, Creative Bioarray has developed a cardiotoxicity testing platform to predict potential structural damage to the myocardium or arrhythmia.
The kidney plays a key role in eliminating drug metabolites. Several drugs, particularly aminoglycosides, have manifested drug-induced nephrotoxicity. Creative Bioarray has developed a range of nephrotoxicity assays for your candidate compounds in early assessment.
Neurotoxicity testing is an essential step for in vitro drug toxicity prediction. Creative Bioarray focuses on using primary cell models to produce greater predictivity. We use high/live content imaging and the sensitive ATP bioluminescence assays to evaluate neurotoxicity.
Drug-drug interactions (DDI) in the body may cause the loss of drug efficacy or unexpected side effects. Different from the usual assays detecting at sub-cellular levels, services at Creative Bioarray are highlighted by assessing DDI at cellular levels. Detection of cytochrome P450 inhibition/induction will be performed with primary or iPS/ES cell-derived hepatocytes.